Dr. Marijo Bilusic, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 173
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME149070 · PA license MD447230 -
Hematology (Internal Medicine) Physician
FL license ME149070 · PA license MD447230 -
Internal Medicine Physician
NJ license 25MA08421000
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Medical Center of Florida, Inc Miami Beach, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 173
- Services billed
- 717
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 186 | 59 |
| Established patient office or other outpatient visit, 30-39 minutes | 58 | 25 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 32 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Miami, FL | 343 |
| Abiraterone Acetate | 281 |
| Xtandi (enzalutamide) | 74 |
| Ondansetron Hcl Other prescribers in Miami, FL | 47 |
| Nubeqa (darolutamide) | 34 |
| Tamsulosin Hcl Other prescribers in Miami, FL | 21 |
| Orgovyx (relugolix) | 18 |
| Erleada (apalutamide) | 18 |
| Dexamethasone Other prescribers in Miami, FL | 17 |
| Gabapentin Other prescribers in Miami, FL | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $65.41 in total to this clinician.
| Janssen Scientific Affairs, LLC | $42.62 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $22.79 |
| Food and Beverage | $65.41 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $85,949 in research payments for these studies, mostly to the institutions running them.
- MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With …
Merck Sharp & Dohme LLC - A phase 3 randomized openlabel study of PF06821497 mevrometostat in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously…
Pfizer Inc. - Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.